IA
IONS icon

Inspire Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Inspire Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$309K Sell
4,120
-731
-15% -$57.7K 0.03% 458
2025
Q4 		$384K Buy
+4,851
New +$365K 0.04% 368

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Inspire Advisors's IONS Position: Q1 2026 in Review

Inspire Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 15% in Q1 2026, selling an estimated $57.7K and leaving 4,120 shares worth $309K. The position accounts for 0.03% of the portfolio, ranked #458.

Inspire Advisors first reported a position in IONS in Q4 2025 and has held it in 2 quarters since. The position peaked at $384K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Inspire Advisors held 4,120 shares of Ionis Pharmaceuticals worth $309K as of Q1 2026.
  • Inspire Advisors sold 731 Ionis Pharmaceuticals shares in Q1 2026, an estimated $57.7K.
  • Ionis Pharmaceuticals made up 0.03% of Inspire Advisors's portfolio in Q1 2026, its #458 holding.
  • Inspire Advisors first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Inspire Advisors's Ionis Pharmaceuticals position peaked at $384K in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Inspire Advisors's 13F filing for Q1 2026, filed 15 May 2026.